Asunto(s)
Arteriopatías Oclusivas/diagnóstico , Pierna/irrigación sanguínea , Problemas Sociales , Arteriopatías Oclusivas/etiología , Arteriopatías Oclusivas/mortalidad , Enfermedad Crónica , Humanos , Claudicación Intermitente/diagnóstico , Claudicación Intermitente/etiología , Claudicación Intermitente/mortalidad , Factores de RiesgoRESUMEN
Eleven patients with immune-complex diseases were studied, that had been subjected to a total of 96 plasmaphereses during the day. The quantitative changes were followed up that developed in the active factors of coagulation after plasmapheresis. The results revealed that the plasma exchange, applied to the patients studied, induced the following changes: For factor I (fibrinogen)--mean = 2.39 +/- 1.19 g% (p greater than 0.005); for factor II (prothrombin)--mean = 55.5 +/- 20.9% (p less than 0.001); for factor V (proaccelerin)--mean = 97.6 +/- 13.8% (p greater than 0.01); for factor VII (proconvertin)--mean = 106.8 +/- 8.0% (p greater than 0.01); for factor VIII (AHG A)--mean = 64.5 +/- 22.7% (p less than 0.01); for factor IX (AHG B)--mean = 51.58 +/- 26.0% (p less than 0.001); for factor X--mean = 46.4 +/- 18.5% (p less than 0.001) and for factor XII--mean = 27.0 +/- 23.8% (p less than 0.001). That should be given consideration for the indications of the patients and their pretreatment for plasmapheresis.
Asunto(s)
Factores de Coagulación Sanguínea/análisis , Plasmaféresis/efectos adversos , Adolescente , Adulto , Artritis Reumatoide/sangre , Artritis Reumatoide/terapia , Femenino , Humanos , Vasculitis por IgA/sangre , Vasculitis por IgA/terapia , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/terapia , Masculino , Persona de Mediana Edad , Vasculitis/sangre , Vasculitis/terapiaRESUMEN
The antilipidemic drugs potentiate the effect of the indirect anticoagulants and their co-medication is difficult, risky and requires often laboratory checks. That is why the hyperlipoproteinemias were treated with wheat bran in the patients with hyperlipoproteinemia and thrombembolic diseases with anticoagulant therapy. Twenty seven patients, aged from 34 to 71 (average age 44,6 years)--21 males and 6 females were treated. The anticoagulant treatment was conducted with syncumar in 21 and with marcoumar and falithrom in 6 patients. The patients were recommended to take wheat bran in a dose of 15-20 g, three times daily, suspended in liquid foods for the improvement of the tase, in the course of 1 and 1/2 to 2 months after meals. The therapeutic hypocoagulemia remained optimal. The total lipids were reduced with 20,2 per cent, cholesterine--with 23,8 per cent and triglycerols with 25%. The reduction is statistically significant. No complications were observed but light flatulence.
Asunto(s)
Anticoagulantes/uso terapéutico , Hiperlipoproteinemias/tratamiento farmacológico , Adulto , Anciano , Fibras de la Dieta/uso terapéutico , Evaluación de Medicamentos , Femenino , Humanos , Hipolipemiantes/uso terapéutico , Lípidos/sangre , Masculino , Persona de Mediana Edad , Tiempo de Tromboplastina Parcial , Factores de Tiempo , TriticumRESUMEN
The paper is a survey on the latest up-to-date data on the character, determination methods, physiology, pathophysiology and clinical significance of one of most important factors of anticoagulation system--antithrombin III. Its normal activity is of essential importance for physiological hemostasis. It could be reduced via diminished production, increased elimination and intensified consumption, particularly in case of concomitant grave states and diseases. The enhanced activity of antithrombin III, found most frequently in the treatment with indirect anticoagulants, renal transplantations, and application of anabolic steroids, has given no data of clinical importance so far. Numerous of the outlined problems remain still not sufficiently elucidated.
Asunto(s)
Antitrombina III/fisiología , Trastornos de la Coagulación Sanguínea/fisiopatología , Hemostasis , Antitrombina III/análisis , Deficiencia de Antitrombina III , Coagulación Intravascular Diseminada/fisiopatología , Embolia/fisiopatología , Humanos , Trombina/antagonistas & inhibidores , Trombosis/fisiopatologíaAsunto(s)
Anticoagulantes/administración & dosificación , Arteriopatías Oclusivas/tratamiento farmacológico , Pierna/irrigación sanguínea , Adulto , Anciano , Coagulación Sanguínea/efectos de los fármacos , Enfermedad Crónica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
On the basis of the studies conducted by the authors on 19 nonbred dogs and 25 rabbits of the strain Cincilla and Belgium giant the normal values of the basis indices of hemostasis were determined: thromboelastography (r+k and ma), amount of fibrinogen, number of thrombocytes, thromoboplastic time, time of recalcification. The obtained data are shown on a table. The obtained data could serve as orienting data in examining hemostasis in dogs and rabbits under various experimental conditions and models for investigating various human pathology.
Asunto(s)
Animales de Laboratorio/fisiología , Hemostasis , Animales , Recuento de Células Sanguíneas , Plaquetas , Perros , Fibrinógeno/análisis , Conejos , Tromboelastografía , Tromboplastina/análisis , Factores de TiempoRESUMEN
Certain new data about the nature of Willebrand factors are discussed, its activity being considered as part of the activity of the antihemolytic factor VIII. An one-stage method for its determination is described based on the absence of thrombocytic aggregation in the presence of ristocetin in the patients with Willebrand disease as well as the illustration of one case.